Wetin na Angioimmunoblastic T-sɛl Limfoma (AITL)? Lɛ wi tɔk bɔt am simpul wan!

Yu dɔn ɛva yɛri bɔt wan sik we gɛt dis kayn strenj nem? Sɔntɛm, dɔktɔ tɛl yu ɔ pɔsin we yu sabi dis nem. Pan ɔl we i kin tan lɛk se i kɔmplikt smɔl, lɛ wi tray fɔ ɔndastand am simpul wan. wetin de apin na we wan kayn difεns sεl na wi bכdi we dεn kכl ``T sεl'' de tכn to kεnsar sεl dεm.

Wetin na angioimmunoblastic T-sεl limfoma (AITL)?

Fɔ tɔk am simpul wan, Angioimmunoblastic T-cell Lymphoma (AITL) na wan kayn kansa we kin apin na di wayt blɔd sɛl dɛn na wi blɔd we dɛn kɔl T lymphocytes, ɔ T cells. Tink bɔt am lɛk di we aw wi bɔdi de fɛt. Dɛn kin fɛt bad tin lɛk vayrɔs ɛn baktri dɛm we kin kam insay wi bɔdi ɛn protɛkt wi frɔm sik. Sɔntɛnde, dɛn T sɛl ya kin ivin pwɛl di kansa sɛl dɛn.

כltu, sכmtεm wan pan dεn `T sεl dεm` kin chenj, dat na fכ chenj, εn bi kεnsar sεl. Dɔn dɛn bad bad kansa sɛl dɛn ya kin bigin fɔ sheb kwik kwik wan ɛn bɔku we pɔsin nɔ ebul fɔ kɔntrol. Na da tɛm de dis kɔndishɔn we dɛn kɔl `AITL` kin apin. dis na kansa we de fכl insay wan sכbgrup we dεn kכl `pεriferal T-sεl limfoma`, we de insay di big grup we dεn kכl `nכn-Hכdgkin T-sεl limfoma`. Dis kansa kin sכmtεm go na ples dεm lεk wi liva, lכng, כ `bon mכro`.

Aw kɔmɔn dis sik we dɛn kɔl AITL?

Infakt, AITL na wan kayn T-sɛl limfoma we nɔ kin bɔku, bɔt ɔltogɛda na kansa we nɔ kin bɔku . Fɔ ɛgzampul, na kɔntri lɛk Amɛrika, na 4% nɔmɔ pan ɔl di wan dɛn we gɛt limfoma na AITL. i de akכnt bak fכ 1% to 2% pan כl di nכn-Hכdgkin limfoma pasεnshכn dεm. I kin mɔs bi pan pipul dɛm wae dɔn pas 65 ia .

Wetin na di sayn dɛm fɔ AITL?

Bikɔs AITL na kansa we de gro fast fast, di sayn dɛm kin sho kwik kwik wan. If yu gɛt ɛni wan pan dɛn tin ya, yu fɔ wɔri:

• Fiva we kin kam ɛn go we nɔ gɛt rizin: Di bɔdi kin jɔs wam ɛn di fiva kin kam, go, ɛn kam bak. Dɛn nɔ go ebul fɔ fɛn ɛni patikyula tin we mek i apin.
• Nayt swet: I de swet so we yu de slip dat di sheet dɛn kin wet.
• I kin it ɔ di skin kin irita: I kin apia ɔlsay na di bɔdi, na say dɛn we gɛt spat, ɔ i kin it ɔltɛm.
• I nɔ izi fɔ blo: Fɔ fil se yu nɔ ebul fɔ blo ivin if yu tray smɔl.
• Joyn swel: Di joyn dεm na di limb dεm kin swel εn i kin fil pen.
• di nipl dεm we swεla: dεn de sho lεk lumps na ples dεm lεk di nεk, di armpit dεm, εn di groin. Bɔku tɛm, dɛn tin ya nɔ kin mek pɔsin fil pen.
• We yu de lɔs yu wet fɔ natin: Yu kin lɔs yu wet wantɛm wantɛm, ilɛksɛf yu nɔ de kɔntrol di tin dɛn we yu de it ɔ yu nɔ de du ɛksasaiz bɔku.

Bikɔs AITL kin afɛkt wi imyun sistɛm , sɔm pipul dɛn we gɛt dis sik kin gɛt tin dɛn we dɛn kɔl ɔtoimyun sik, we na sik dɛn we wi yon imyun sistɛm kin tɔn agens wi. fכ egzampl, kכndyushכn dεm lεk imyun trombosaytopenia (lכw bכdi pletlet) כ כtoimyun hεmolaytik anemia (dεstrukshכn fכ blכd sεl dεm).

Wetin kin mek pɔsin gɛt AITL?

AITL kin apin we wi T sεl dεm nכ de nכmal εn bigin fכ gro we wi nכ de kכntrol. Bɔt di wan dɛn we de stɔdi bɔt dis stil nɔ shɔ wetin mek sɔm pipul dɛn kin gɛt dis kayn T-sɛl limfoma ɛn ɔda wan dɛn nɔ kin gɛt am.

I pɔsibul fɔ mek wan link de bitwin AITL ɛn vayral infɛkshɔn lɛk di Epstein-Barr vayrɔs. Bɔt wi nid fɔ no mɔ fɔ ɔndastand aw dis link de wok.

Aw dɛn kin no se pɔsin gɛt AITL?

Bɔku tɛm dɛn kin no AITL tru wan limf node bayɔpsi . Dis involv fɔ tek smɔl sampul pan di tisu frɔm wan limf node we dɔn swel ɔ say we dɛn tink se dɛn de tink ɛn chɛk am ɔnda maykroskɔp. If yu test rizulyt sho abnכmal T limfosayt, dכkta dεm go sכspεkt AITL.

Wae dɛn dɔn kɔnfirm de diagnosis, wan oncologist go ɛgzamin yu ɛn aks yu bɔt yu symptoms. Dɛn go aks bak bɔt yu wɛl bɔdi istri, lɛk di sik dɛn we yu bin dɔn gɛt trade ɛn di mɛrɛsin dɛn we yu de tek naw.

Apat frɔm dat, di dɔktɔ kin du bɔku tɛst dɛn bak, lɛk:

• Blɔd tɛst dɛn.
• Bɔn mɛrɔ bayɔpsi.

Yu kin gɛt imej tɛst dɛn bak lɛk dɛn wan ya:

• CT skan (CT - kɔmpyuta tomografi skan dɛn).
• MRI skan (MRI - magnεtik rεsכnans imej skan).
• PET skan (positron emission tomografi skan dɛn).

AITL, lɛk ɔda limfoma, kin at fɔ no. Dis na bikɔs di sik kin kɔmpleks, ɛn de sik kin kam smɔl smɔl ɛn kin tan lɛk ɔda sik dɛn. Fɔ dɛn rizin ya, bɔku pan di wan dɛn we gɛt AITL kin no se dɛn gɛt dis sik let stej . Bɔt di wan dɛn we de stɔdi bɔt dis de kɔntinyu fɔ fɛn we fɔ no AITL ɛn ɔda limfoma dɛn kwik kwik wan.

Aw dɛn kin trit AITL?

Di tritmɛnt fɔ AITL de dipen pan bɔku tin dɛm, lɛk di sayn dɛm wae yu gɛt, aw de sik tranga, ɛn yu ɔl wɛl bɔdi. Di men tritmɛnt fɔ AITL na:

• Kimotɛrapi: .Dis min se dɛn fɔ gi difrɛn mɛrɛsin dɛn we dɛn jɔyn fɔ kil di kansa sɛl dɛn. Dɛn kin ad stɛroyd dɛn bak to dis. Di tritmɛnt dɛm we dɛn kin yuz mɔ na CHOP ɛn BV+CHP. Di nem CHOP na akɔdin fɔ Saytoksan (sayklɔfosfamid), Haydroksidaunɔrubisin (haydroksidaunɔrubisin), Ɔnkɔvin (vinkristin sɔlfɛt), ɛn Prɛdnisɔn. BV+CHP na wan kכmbaynshכn fכ brentuximab vεdotin, sayklofosfamid, dכksorubisin, εn prεdnison. Dis kin kɔmplikt smɔl, bɔt yu dɔktɔ go ɛksplen am to yu.

• stεm sεl transplant: Dis involv fכ pul di kεnsar stem sεl dεm εn put hεlty stεm sεl dεm. dis hεlty sεl dεm kin tek frכm yu (`autologous`) כ dεn kin gi dεm frכm כda pכsin (`allogeneic`).

• Targeted therapy: Dis tritmεnt de fכs כnli pan di jεnεtik mכtεshכn dεm we de tכn hεlty sεl dεm to kεnsar sεl dεm. Dis min se di drɔg de go stret to di bad sɛl dɛn ɛn i de wok pan dɛn bad sɛl dɛn de nɔmɔ.

Aw lɔŋ yu kin liv wit AITL?

AITL na kansa we nɔ kin rili bad. Risach sho se di midyan layf afta dɛn no di sik nɔ rich tri ia . Di "midya" na di midul valyu insay wan rεnj כf valyu dεm. Dis min se sɔm pipul dɛn kin liv shɔt layf, ɛn ɔda wan dɛn kin liv lɔng.

Bɔt na wan impɔtant pɔynt: Na lɛk 30% to 35% pan di pipul dɛm wae gɛt AITL kin ansa fayn fayn wan to tritmɛnt ɛn dɛn kin ivin wɛl we di kansa nɔ kam bak.

Survival Rate fɔ AITL

di fayv ia sכvayv rεt fכ AITL de bitwin 30% εn 35% . Dis min se pan 100 pipul dɛm wae dɛn dɔn no se gɛt AITL, bitwin 30 ɛn 35 pipul dɛm stil de alayv afta fayv ia. Semweso, di sεvin ia sכvayv rεt de arawnd 29%.

Na nɔmal tin fɔ mek yu fil fred ɛn wɔri we yu si dɛn statystik ya. Bɔt mɛmba se dɛn tin ya na jɔs ɛstimat. Dɛn kin kɔmɔt frɔm wetin ɔda pipul dɛn dɔn gɛt di sem sik lɛk yu. Ɔlman in wɛlbɔdi istri ɛn in jenɛtik bakgrɔn difrɛn. So, dɛn kayn pipul ya wae de liv nɔr kin ebul fɔ no aw lɔng yu go liv ɔr aw yu go ansa to tritmɛnt.

If yu de wɔri bɔt dɛn statystik ya, ɔ if yu want fɔ no aw dɛn kin afɛkt yu, mek shɔ se yu tɔk to yu dɔktɔ. I kin ɛksplen yu sityueshɔn ɛn gi yu ɛni ɛp we yu nid.

Yu tink se dɛn kin ebul fɔ stɔp AITL?

Bɔrku pipul dɛm wae gɛt AITL nɔr gɛt ɛni risk factor wae dɛn no bɔt fɔ gɛt dis sik. No patikyula we nɔ de fɔ mek yu nɔ gɛt AITL ɔ ɛni ɔda kayn limfoma. Lɛk bɔrku kansa, dis na tin wae kin apun sɔmtɛm. I nɔ min se yu du ɛnitin we nɔ rayt.

A kin ridyus di prɔblɛm we a gɛt?

Pan ɔl we yu nɔ go ebul fɔ mek yu nɔ gɛt angioimmunoblastic T-cell lymphoma, yu kin du dɛn tin ya fɔ mek yu gɛt wɛlbɔdi imyun sistɛm :

• It fayn it: It tin dɛn we gɛt bɔku vɛjitebul, frut, ligɛm, ɔl gren, ɛn prɔtin, lɛk mit ɛn fish we nɔ gɛt bɛtɛ trɛnk.
• Ɛksesaiz ɔltɛm: Du sɔntin lɛk fɔ waka ɔ rɔn fɔ at le 30 minit ɛvride.
• Gɛt gud slip: Gɛt at le 7-8 awa fayn slip insay wan de.
• Mek yu gɛt wɛlbɔdi wet we go fayn fɔ yu.
• Nɔ smok ɛn yuz tabak: Lɛk sigrɛt ɛn bidis, tabak we nɔ gɛt smok (lɛk fɔ chɛw tabak ɛn chɛwing gam) kin ambɔg bak. Vaping sɛf nɔ fayn.
• Limit fɔ drink rɔm.

Ustɛm a fɔ go to dɔktɔ?

If yu gɛt sɔm sayn dɛn lɛk we yu gɛt rɔsh wantɛm wantɛm, yu limf no dɛn we swel, yu gɛt ay fiva, ɔ yu nɔ gɛt bɔku bɔku bɔdi we yu nɔ bin want, go to dɔktɔ wantɛm wantɛm.

If dɛn dɔn ɔlrɛdi gɛt tritmɛnt fɔ AITL, tɛl yu ɔnkɔlɔjis wantɛm wantɛm if yu gɛt nyu sik ɔ if yu sik de wɔs wantɛm wantɛm. We yu tink bɔt aw dis kansa tan, i rili impɔtant fɔ bigin tritmɛnt kwik kwik wan.

AITL de afɛkt ɔlman difrɛn we. Na yu dɔktɔ nɔmɔ go ebul fɔ ɛksplen aw di sik we yu gɛt go afɛkt yu. Sɔm pipul dɛn nɔ kin want fɔ no di ditel bɔt di sik, ɛn dat nɔ bad. Yu gɛt rayt fɔ disayd bɔt di tritmɛnt we yu go gɛt. Na yu nɔmɔ no wetin bɛtɛ fɔ yu maynd, filin, ɛn spiritual wɛlbɔdi.

Us kwɛstyɔn dɛn a fɔ aks mi dɔktɔ?

Na nɔmal tin fɔ gɛt bɔku kwɛstyɔn afta dɛn dɔn no se yu gɛt AITL. Na sɔm kwɛstyɔn dɛn ya yu kin aks yu dɔktɔ we de mɛn kansa:

• Aw mi kansa dɔn go bifo?
• Di kansa dɔn skata to mi ɔda pat dɛn?
• Us tritmɛnt opshɔn dɛn a gɛt?
• Aw kwik a fɔ bigin tritmɛnt?
• A kin kɔntinyu fɔ du mi wok we a de gɛt tritmɛnt?
• Us kayn sɔpɔt ɛn ɛp a go nid we a de du tritmɛnt?
• A kin jɔyn sɔpɔt grup ɔ ɔda tin dɛn?
• Aw a go kɔntinyu fɔ gɛt wɛlbɔdi?

We pɔsin no se i gɛt kansa, i kin mek i gɛt difrɛn difrɛn tin dɛn we nɔ izi fɔ am, lɛk fɔ fil bad, wɔri, fɔ vɛks, ɛn fɔ vɛks. Bikɔs AITL na sik wae nɔr kin bɔrku, yu kin fil lɛk yu wan ɛn lɛk se nɔbɔdi nɔr ɔndastand yu.Bɔt yu mɛdikal tim de fɔ ɛp yu. Dɛn kin tɛl yu bɔt di tin dɛm wae yu nid, ɛn sɔpɔt grup wit pipul dɛm wae dɔn pas di sem tin dɛm lɛk yu. Yu nɔ nid fɔ go tru dis waka yu wan. Gɛt di sɔpɔt fɔ di wan dɛn we yu lɛk ɛn yu dɔktɔ dɛn.

Mɛsej we dɛn kin kɛr go na os

AITL na wan siriɔs kansa ɛn we nɔ kin bɔku. Bɔt i impɔtant fɔ no bɔt am, pe atɛnshɔn to di sayn dɛm, ɛn go to dɔktɔ kwik kwik wan.

• No di sayn dɛm: Wach yusɛf fɔ fiva we yu nɔ ɛksplen, swet na nɛt, ankles we swel, prɔblɛm wit yu skin, i nɔ izi fɔ blo, yu jɔyn dɛn we swel, ɛn we yu nɔ gɛt bɔku bɔku wet.
• Go to dɔktɔ: If yu gɛt dawt, go to dɔktɔ wantɛm wantɛm. Fɔ no di sik kwik kwik wan ɛn fɔ trit am rili impɔtant.
• Tritmɛnt dɛn de: Sɔm tin dɛn de we yu kin pik lɛk kemotɛrapi, stem sɛl transplant, ɛn tritmɛnt dɛn we dɛn kin tɔk to. Yu dɔktɔ go disayd wetin bɛtɛ fɔ yu.
• Nɔto yu wan de: Dis waka kin tranga, bɔt yu gɛt fambul dɛn, padi dɛn, ɛn dɔktɔ dɛn fɔ ɛp yu. Gɛt dɛn sɔpɔt.
• Stay positive: Statistics nɔto ɔltin. Ɔlman difrɛn. Stay wit op.

A op se dis infɔmeshɔn dɔn ɛp yu fɔ gɛt sɔm ɔndastandin bɔt dis sik. Mɛmba se i bɛtɛ fɔ mek yu go to dɔktɔ fɔ ɛni wɛlbɔdi prɔblɛm.

` AITL, Angioimmunoblastic T-cell Lymphoma, T-cell lymphoma, kansa, blɔd kansa, limfoma simptom dɛm, kansa tritmɛnt